{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:35:30Z","timestamp":1787312130516,"version":"build-2736575974"},"reference-count":31,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,2,24]],"date-time":"2020-02-24T00:00:00Z","timestamp":1582502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["T004517N"],"award-info":[{"award-number":["T004517N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006282","name":"Koning Boudewijnstichting","doi-asserted-by":"publisher","award":["J5810650"],"award-info":[{"award-number":["J5810650"]}],"id":[{"id":"10.13039\/501100006282","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Micha\u00ebl Van Waeyenberge Fonds","award":["J5810650"],"award-info":[{"award-number":["J5810650"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>In invasive aspergillosis (IA), an early and adequate assessment of the response to the initial antifungal therapy remains problematic. We retrospectively analyzed 206 hematology patients with proven or probable IA, and collected serial serum galactomannan (sGM) values and survival status through week 6 and week 12. We created a model for survival at week 6 based on the sGM taken at baseline and on early sGM kinetics. This resulted in a rule predicting that patients with a baseline sGM index &gt;1.4, who failed to lower that index to &lt;0.5 after one week, had a mortality rate of 48.1% at week 6. Conversely, patients presenting with a baseline sGM index \u22641.4 that obtained a negative sGM (&lt;0.5) after one week, had a mortality that was almost five times lower at only 10.1% by week 6. These findings were confirmed in an external cohort from an independent prospective study. In conclusion, sGM kinetics correlate well with treatment outcomes in hematology patients with IA. We present a rule which is easy to use at the bedside and has good accuracy in predicting week 6 survival.<\/jats:p>","DOI":"10.3390\/jcm9020610","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T08:12:22Z","timestamp":1582618342000},"page":"610","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["A Mortality Prediction Rule for Hematology Patients with Invasive Aspergillosis Based on Serum Galactomannan Kinetics"],"prefix":"10.3390","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1517-6426","authenticated-orcid":false,"given":"Toine","family":"Mercier","sequence":"first","affiliation":[{"name":"KU Leuven, Department of Microbiology, Immunology and Transplantation, 3000 Leuven, Belgium"},{"name":"Department of Hematology, University Hospitals Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Wera","sequence":"additional","affiliation":[{"name":"Department of Hematology, University Hospitals Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9640-0791","authenticated-orcid":false,"given":"Louis Y. A.","family":"Chai","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, University Medicine Cluster, National University Health System, Singapore and Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119074, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8668-1350","authenticated-orcid":false,"given":"Katrien","family":"Lagrou","sequence":"additional","affiliation":[{"name":"KU Leuven, Department of Microbiology, Immunology and Transplantation, 3000 Leuven, Belgium"},{"name":"Department of Laboratory Medicine and National Reference Center for Mycosis, University Hospitals Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Maertens","sequence":"additional","affiliation":[{"name":"KU Leuven, Department of Microbiology, Immunology and Transplantation, 3000 Leuven, Belgium"},{"name":"Department of Hematology, University Hospitals Leuven, 3000 Leuven, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,24]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"i19","DOI":"10.1093\/jac\/dkx030","article-title":"Early diagnosis of invasive mould infections and disease","volume":"72","author":"Lamoth","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_2","first-page":"341","article-title":"Pulmonary aspergillosis: Early diagnosis improves survival","volume":"62","author":"Roos","year":"1995","journal-title":"Respir. Int. Rev. Thorac. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1128\/AAC.00673-10","article-title":"The Initial 96 Hours of Invasive Pulmonary Aspergillosis: Histopathology, Comparative Kinetics of Galactomannan and (1\u21923)-\u03b2-d-Glucan, and Consequences of Delayed Antifungal Therapy","volume":"54","author":"Hope","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1086\/588660","article-title":"Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer\/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC\/MSG) Consensus Group","volume":"46","author":"Walsh","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/503427","article-title":"Diagnosis of Invasive Aspergillosis Using a Galactomannan Assay: A Meta-Analysis","volume":"42","author":"Pfeiffer","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1093\/cid\/ciw592","article-title":"Galactomannan, \u03b2-D-Glucan, and Polymerase Chain Reaction\u2013Based Assays for the Diagnosis of Invasive Fungal Disease in Pediatric Cancer and Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis","volume":"63","author":"Lehrnbecher","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1093\/cid\/civ555","article-title":"Galactomannan and Polymerase Chain Reaction\u2013Based Screening for Invasive Aspergillosis Among High-Risk Hematology Patients: A Diagnostic Meta-analysis","volume":"61","author":"Arvanitis","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_8","first-page":"CD007394","article-title":"Galactomannan detection for invasive aspergillosis in immunocompromised patients","volume":"2015","author":"Leeflang","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1086\/590566","article-title":"Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria","volume":"47","author":"Segal","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cncr.22738","article-title":"Immune reconstitution inflammatory syndrome in cancer patients with pulmonary aspergillosis recovering from neutropenia: Proof of principle, description, and clinical and research implications","volume":"110","author":"Miceli","year":"2007","journal-title":"Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1469-0691.2005.01349.x","article-title":"Comparison of three methodologies for the determination of pulmonary fungal burden in experimental murine aspergillosis","volume":"12","author":"Sheppard","year":"2006","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1093\/jac\/dkw098","article-title":"Pharmacodynamics of isavuconazole in experimental invasive pulmonary aspergillosis: Implications for clinical breakpoints","volume":"71","author":"Kovanda","year":"2016","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1128\/AAC.46.1.12-23.2002","article-title":"Antifungal Efficacy of Caspofungin (MK-0991) in Experimental Pulmonary Aspergillosis in Persistently Neutropenic Rabbits: Pharmacokinetics, Drug Disposition, and Relationship to Galactomannan Antigenemia","volume":"46","author":"Petraitiene","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1093\/infdis\/155.5.1005","article-title":"Receptor-mediated clearance of Aspergillus galactomannan","volume":"155","author":"Bennett","year":"1987","journal-title":"J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.2169\/internalmedicine.53.2381","article-title":"Diagnostic value of the serum galactomannan and (1, 3)-\u03b2-D-glucan assays for invasive pulmonary aspergillosis in non-neutropenic patients","volume":"53","author":"Cai","year":"2014","journal-title":"Intern. Med. Tokyo Jpn."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7326\/M13-2508","article-title":"Combination Antifungal Therapy for Invasive Aspergillosis: A Randomized Trial","volume":"162","author":"Marr","year":"2015","journal-title":"Ann. Intern. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1002\/cncr.23441","article-title":"Changes in causes of death over time after treatment for invasive aspergillosis","volume":"112","author":"Wingard","year":"2008","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/mpr.329","article-title":"Multiple Imputation by Chained Equations: What is it and how does it work?","volume":"20","author":"Azur","year":"2011","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","article-title":"Index for rating diagnostic tests","volume":"3","author":"Youden","year":"1950","journal-title":"Cancer"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1056\/NEJMoa020191","article-title":"Voriconazole versus Amphotericin B for Primary Therapy of Invasive Aspergillosis","volume":"347","author":"Herbrecht","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet Lond. Engl."},{"key":"ref_22","unstructured":"Donnelly, J.P., Chen, S.C., Kauffman, C.A., Steinbach, W.J., Baddley, J.W., Verweij, P.E., Clancy, C.J., Wingard, J.R., Lockhart, S.R., and Groll, A.H. (2019). Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clin. Infect. Dis., (epub ahead of print)."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"661","DOI":"10.3389\/fmicb.2018.00661","article-title":"Galactomannan, a Surrogate Marker for Outcome in Invasive Aspergillosis: Finally Coming of Age","volume":"9","author":"Mercier","year":"2018","journal-title":"Front. Microbiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2330","DOI":"10.1128\/JCM.06513-11","article-title":"Early Serum Galactomannan Trend as a Predictor of Outcome of Invasive Aspergillosis","volume":"50","author":"Chai","year":"2012","journal-title":"J. Clin. Microbiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1093\/cid\/cix198","article-title":"Pharmacodynamics of Isavuconazole for Invasive Mold Disease: Role of Galactomannan for Real-Time Monitoring of Therapeutic Response","volume":"64","author":"Kovanda","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s10928-017-9509-1","article-title":"Prognostic value of galactomannan: Current evidence for monitoring response to antifungal therapy in patients with invasive aspergillosis","volume":"44","author":"Kovanda","year":"2017","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1086\/343804","article-title":"Use of Circulating Galactomannan Screening for Early Diagnosis of Invasive Aspergillosis in Allogeneic Stem Cell Transplant Recipients","volume":"186","author":"Maertens","year":"2002","journal-title":"J. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/cid\/cit393","article-title":"The Serum Galactomannan Index Predicts Mortality in Hematopoietic Stem Cell Transplant Recipients With Invasive Aspergillosis","volume":"57","author":"Fisher","year":"2013","journal-title":"Clin. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jmii.2017.05.007","article-title":"Clinical characteristics, radiologic findings, risk factors and outcomes of serum galactomannan-negative invasive pulmonary aspergillosis","volume":"51","author":"Jung","year":"2017","journal-title":"J. Microbiol. Immunol. Infect. Wei Mian Yu Gan Ran Za Zhi"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Neofytos, D., Railkar, R., Mullane, K.M., Fredricks, D.N., Granwehr, B., Marr, K.A., Almyroudis, N.G., Kontoyiannis, D.P., Maertens, J., and Fox, R. (2015). Correlation between Circulating Fungal Biomarkers and Clinical Outcome in Invasive Aspergillosis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0129022"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3346\/jkms.2014.29.1.61","article-title":"Success rate and risk factors for failure of empirical antifungal therapy with itraconazole in patients with hematological malignancies: A multicenter, prospective, open-label, observational study in Korea","volume":"29","author":"Kim","year":"2014","journal-title":"J. Korean Med. Sci."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/2\/610\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:01:21Z","timestamp":1760173281000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/9\/2\/610"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,24]]},"references-count":31,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["jcm9020610"],"URL":"https:\/\/doi.org\/10.3390\/jcm9020610","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,24]]}}}